Cancer arises through the acquisition of genetic and epigenetic changes that drive tumorigenesis. While most efforts to understand the origins of these entities have focused on the identification and functional characterization of somatic single nucleotide variants (SNVs) that activate oncogenes or inactivate tumour suppressors, the vast majority of human cancers also harbour large copy number variants (CNVs) that impact gene dosage through gain or loss of whole chromosomes or chromosome segments 1 . For example, recurrent segmental deletions-such as those affecting chromosome 17p-are extremely common in human cancers yet are widely considered to arise because of selection for a single 'driver' in the deleted region, with the adjacent gene losses reflecting 'passenger' events that have no effect on tumour phenotypes. However, evidence is emerging from short hairpin RNA (shRNA) screens and bioinformatic approaches that these lesions may target more than one relevant activity [2] [3] [4] [5] . If true, then the impact of segmental deletions on tumour development would be fundamentally distinct from SNVs, yet, given their frequent occurrence, disproportionately understudied.
Chromosome 17p configurations in human cancer
We decided to study 17p deletion as a prototype of a recurrent cancerassociated deletion owing to its high frequency and invariable inclusion of TP53, an extensively studied tumour suppressor gene that is considered to be the major driver of 17p loss 6, 7 . To characterize better the nature and scope of these deletions, we analysed genomic data from 4,994 tumours across 18 cancer types (http://www.cbioportal.org; accessed 29 October 2014). This survey confirmed previous indications that mutation and/or deletion of the TP53 tumour suppressor gene occurs in approximately ~50% of all human cancers 8 . We then classified 17p-altered tumours as to whether they displayed TP53 mutation (encompassing missense, nonsense and frameshift mutations), deletion (as defined by a reduction in TP53 copy number), or both (Fig. 1a) . The most common TP53 configuration involves a missense mutation together with a segmental 17p deletion, although a substantial fraction of p53-altered tumours harboured chromosome 17p deletion together with an apparently wild-type TP53 allele. Similar results were observed in blood cancers, in which TP53 mutations and/or 17p loss are less common but are linked to a particularly dismal prognosis 9, 10 . Hence, the frequency of 17p deletion may even exceed point mutations within the TP53 gene.
Chromosome 17p deletions frequently encompass all or most of the chromosome arm (Fig. 1b) . In addition to TP53, this region encodes over 300 protein-coding genes that include other established or putative tumour suppressors [11] [12] [13] . Unexpectedly, TP53 was not identified as a candidate tumour suppressor in non-Hodgkin lymphoma or acute myeloid leukaemia (AML) using GISTIC, an algorithm designed to pinpoint candidate drivers from CNV data by identifying 'epicentres' of gain or loss 14 ( Fig. 1b and Extended Data Fig. 1b) . Moreover, AMLs harbouring a TP53 mutation together with a 17p deletion displayed a worse prognosis than those harbouring TP53 mutations alone ( Fig. 1c and Extended Data Fig. 1c) . Collectively, these data raise the possibility that additional genes drive selection for 17p loss during tumorigenesis.
Modelling 17p13 deletions in the mouse
We decided to test this hypothesis in mice. To produce a strain capable of modelling somatic 17p deletions, we used the MICER chromosome engineering strategy developed previously 15 to introduce loxP sites and a split HPRT gene into chromosomal regions flanking the Alox12 and Sco1 genes on mouse chromosome 11B3, which is a 4 Mb region on mouse chromosome 11 that is syntenic to human 17p13.1 (Fig. 2a, b and Extended Data Fig. 2a, b) . Candidate clones were treated with adenovirus (Adeno)-cre to recombine the 11B3 region, selected in
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hypoxanthine-aminopterin-thymidine (HAT) medium, and subjected to a polymerase chain reaction (PCR) analysis to discriminate between cis and trans recombination events (Extended Data Fig. 2c ). This readily identified embryonic stem (ES) cell clones harbouring loxP sites flanking 11B3 in cis and revealed that 11B3 deletion is not deleterious to ES cells (data not shown). We refer to the appropriately targeted allele above as 11B3 flox (11B3 fl ). 11B3 fl mice were produced by blastocyst injection and crossed to a variety of constitutive and haematopoietic-directed Cre mouse lines. We never observed viable progeny harbouring a recombined 11B3 deletion arising from 11B3 fl crosses with Ella-cre or constitutive CAG-cre mice, implying that heterozygous deletion of the 11B3 interval confers embryonic lethality. However, double-mutant progeny harbouring the cre transgene and an unrecombined 11B3 fl allele were produced (Extended Data Table 1 ), perhaps surviving owing to inefficient recombination between the two distant (~4 Mb) loxP sites.
As in ES cells, somatic 11B3 deletion in the haematopoietic compartment was not an obligate cell lethal event; thus, recombined cells were detected in the peripheral blood of 11B3 fl/+ mice crossed to strains harbouring Cd19-cre, Mx1-cre or Vav1-cre alleles (Extended Data Fig. 3a) . Nevertheless, the apparent recombination frequency was substantially lower than observed in progeny of conditional Trp53-knockout mice crossed to the same strains (20% versus 100%; Extended Data Fig. 3b, c) . While such differences can complicate direct comparisons of tumour onset between 11B3 fl and Trp53 fl animals, we reasoned that changes in the fraction of 11B3-deleted cells over time should indicate whether 11B3 loss provides a competitive advantage during tumorigenesis.
We first tested whether somatic deletion of 11B3 could drive cancer development in the Eμ-Myc transgenic model of non-Hodgkin lymphoma, as Trp53 deletion potently accelerates lymphomagenesis in this model 16, 17 and because 17p alterations are associated with adverse prognosis in the corresponding human disease 18 (Extended Data Fig. 1c ). Accordingly, Eμ-Myc mice were crossed to the 11B3 fl allele and a Vav1-cre transgenic strain, and the resulting progeny were monitored for tumour onset (Fig. 2c) . Mice harbouring the 11B3 fl allele developed lymphomas much more rapidly than controls (59 versus 130 days, P < 0.001), clearly indicating that loss of the 11B3 region can promote tumorigenesis.
Paradoxically, Eμ-Myc;Trp53 fl/+ ;Vav1-cre mice developed lymphomas even more rapidly than Eμ-Myc;11B3 fl/+ ;Vav1-cre animals (Extended Data Fig. 3d ). While this observation is consistent with a potentially negative impact of 11B3 deletion on cellular fitness, it might also reflect the nearly fivefold reduced recombination efficiency of the 11B3 fl versus Trp53 fl alleles. Consistent with the idea of reduced recombination efficiency, semi-quantitative and quantitative (q)PCR analysis indicated a massive enrichment in the fraction of 11B3-deleted cells in lymphomas compared with the premalignant setting (~100% versus 15%; Fig. 2d, e) , which was confirmed by genome sequencing (Fig. 2f) . Although lymphomas arising in the Trp53 fl/+ and 11B3 fl/+ animals were both highly disseminated, 11B3-deleted lymphomas typically presented 
as a more mature B-cell type and showed enhanced resistance to certain chemotherapeutic agents (Extended Data Fig. 4a-c) . Thus, 11B3 deletion confers a selective advantage during lymphomagenesis and produces phenotypes distinct from a Trp53-null setting.
p53 is induced after DNA damage, when it activates transcription of target genes involved in cell cycle arrest, apoptosis, and other cellular processes 19, 20 . Strikingly, all 11B3-deleted lymphomas showed either high or undetectable levels of p53 protein, and none were capable of inducing the p53 transcriptional target p21 (also known as Cdkn1a) after treatment with the DNA-damaging chemotherapeutic drug adriamycin (ADR). Such a pattern is reminiscent of lymphoma cells that acquire inactivating Trp53 mutations 21, 22 and indeed, most 11B3-deleted lymphomas (75%) acquired missense or nonsense mutations in the remaining wild-type Trp53 allele (Extended Data Fig. 4f ). Other 11B3-deleted lymphomas displayed no p53 activity, suggesting that each acquired some other mutational or epigenetic event that disabled the intact wild-type Trp53 allele. Regardless, the majority of 11B3-deleted lymphomas display chromosome configurations analogous to the common TP53 mutation/deletion events observed in human cancers ( Fig. 1a and Fig. 2g ).
We also tested the mechanisms of loss of heterozygosity (LOH) arising in conventional Trp53-mutant mouse models. To this end, we generated Eμ-Myc strains with the following additional alleles: Trp53
LSL-R172H/+ , and analysed the fate of the remaining Trp53 allele upon lymphoma manifestation using a qPCR assay to detect the copy number of select regions flanking Trp53. In these models LOH clearly does not involve deletion of the remaining Trp53 locus, as the genes proximal and distal to Trp53 (for example, Eif5a and Sco1/Alox12, respectively) remained diploid in all cases (Extended Data Fig. 5a ). Instead, this analysis suggests that LOH occurs through duplication of the targeted mutant Trp53 allele, a conclusion that was confirmed by analysis of polymorphic markers in this region ( Fig. 2g and Extended Data Fig. 5b, c) . While such 17p configurations occur in human tumours, they are less frequent than those involving large deletions (see Fig. 1a ).
Role of 11B3 deletion in lymphomagenesis
Although the data described earlier demonstrate that 11B3 deletion can contribute to tumorigenesis, the differences in recombination frequencies between the conditional 11B3 and Trp53 alleles made it impossible to assess whether other genes in the 11B3 deletion contribute to its effects. To mitigate this caveat without extensive strain intercrossing, we exploited the capability of shRNAs to suppress gene expression in trans, hypothesizing that any phenotypic differences arising between wildtype and 11B3-deleted cells expressing a potent Trp53 shRNA would be independent of Trp53. As immunoblotting and qPCR with reverse transcription (RT-qPCR) analysis confirmed that our Trp53 shRNA was equally capable of disabling Trp53 in pre-B cells harbouring one or two Trp53 alleles (Extended Data Fig. 6 ), we co-transduced pre-B cells derived from the bone marrow of Vav1-cre and Vav1-cre;11B3 fl/+ mice with a Myc complementary DNA (linked to GFP) and the Trp53 shRNA (linked to mCherry) and studied tumorigenesis upon their transplantation into irradiated recipient mice.
Mice receiving cells harbouring the conditional 11B3 deletion and the Trp53 shRNA developed tumours more rapidly than those transplanted with cells harbouring the Trp53 shRNA alone ( Fig. 3a ; median onset 28 versus 36 days, P < 0.01). In both the 11B3 fl/+ and 11B3
settings, the disease presented as an aggressive B-cell malignancy (data not shown) in which p53 protein and activity were undetectable (Fig. 3b) . Furthermore, the subsequent lymphomas were double positive for GFP and mCherry, indicating that they retained the Myc cDNA and Trp53 shRNA (data not shown). While only 15-20% of the premalignant cells underwent 11B3 recombination, almost all of the resulting lymphoma cells harboured this deletion (Fig. 3c) . Thus, 11B3 deletion confers a strong selective advantage even in the absence of detectable p53 function.
To identify genetic elements within the 11B3 interval that act together with Trp53 to suppress lymphoma development, we first took a candidate gene approach. We noted that virtually all lymphomaassociated 17p deletions encompass both TP53 and E1F5A (see Fig. 1b ), the latter gene also having been identified as a tumour suppressor that promotes apoptosis 11 . To examine interactions between these genes during lymphomagenesis, validated shRNAs targeting Trp53 and/or Eif5a, co-expressed in tandem, were introduced into Eμ-Myc haematopoietic stem and progenitor cells (HSPCs) and then transplanted into syngeneic recipients. As expected, suppression of either Trp53 or Eif5a accelerated lymphomagenesis relative to controls, which did not develop tumours over the time of evaluation ( Fig. 4a ; median onset 56 and 99.5 days, respectively). Still, co-suppression of both Trp53 and Eif5a produced lymphomas even more rapidly (median onset 45 days). Apparently, premalignant cells co-suppressing Trp53 and Eif5a shRNAs have an increased selective advantage compared with cells expressing either shRNA alone, a suggestion that was confirmed by an in vivo competition assay (Extended Data Fig. 7 ) and apoptosis measurements in premalignant cells (Fig. 4b ) 16, 23, 24 . Although our shRNA technology cannot precisely mimic the gene dosage produced by a heterozygous gene deletion, these data identify Eif5a as a second gene in the 11B3 interval that can contribute to its activity.
To test whether additional 17p13 genes have a role, we generated a shRNA library targeting the ~100 protein-coding genes in the 11B3 region (exclusive of Trp53 and Eif5a) and screened it for tumourpromoting activity in HSPC transplantation assays ( Fig. 4c; 17p13 shRNA library detailed in Supplementary Table 1) . Compared with controls, these libraries accelerated lymphomagenesis in recipient mice, implying that one or more shRNAs conferred a selective advantage (Fig. 4d) . To identify such shRNAs, PCR products amplified from genomic DNA were subject to deep sequencing and the abundance of each shRNA compared to the initial pool. Forty shRNAs targeting 17 genes were enriched in tumours compared to the injected population (Supplementary Table 1) .
Among the potential candidates, two shRNAs targeting Alox15b (shAlox15b.1252 and shAlox15b.2865), showed a 245-and 50-fold enrichment, respectively, compared with their representation in the initial library (Extended Data Fig. 8a ). We thus tested whether suppression of Alox15b alone or in combination with Trp53 could accelerate tumorigenesis as was done for Eif5a. Recipients of HSPCs targeted with Alox15b shRNAs had significantly shorter lymphoma-free survival than shRen controls (Fig. 4e) , and those receiving HSPCs harbouring Alox15b-Trp53 tandem shRNA showed a further acceleration over shTrp53-shRen controls (Fig. 4f) . 
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Partial knockdown of Alox15b by shRNAs in NIH3T3 cells resulted in accumulation of its substrate, arachidonic acid (AA) (Extended Data Fig. 8b, c) , and higher AA levels were detected in 11B3-deleted lymphoma cells compared with their Trp53-null counterparts (Extended Data Fig. 8d) . Interestingly, AA suppresses apoptosis in certain cancer cells 25 and, in agreement, exogenous AA inhibited apoptosis of pre-B cells in a dose-dependent manner (Extended Data  Fig. 8e ). While a complete mechanistic understanding of its effects will require further work, these studies pinpoint Alox15b as an additional tumour suppressor in the 11B3 region. Intriguingly, shRNAs targeting two other Alox family genes adjacent to Alox15b were enriched in our screen (Alox12b, Alox3e), raising the possibility that 17p deletion coordinately attenuates the output of this gene family. Additionally, beyond protein-coding genes, the reduced dosage of non-coding RNAs not tested in our screen might contribute to the activity of 17p deletions 26 .
11B3 deletion contributes to AML
We also asked whether 11B3 loss would enhance tumorigenesis in a genetically and pathologically accurate mouse model of complexkaryotype AML, an invariably lethal leukaemia subtype 9, 27, 28 . In this disease, TP53 lesions often co-occur with NF1 loss and deletions on 5q and/or 7q, which can be approximated in mice transplanted with Trp53 −/− HSPCs co-expressing shRNAs targeting Nf1 and Mll3 (also known as Kmt2c) (encoded on human 7q36) 29 . Taking advantage of the flexibility of this model, we compared disease onset and pathology in mice transplanted with shNf1-shMll3-transduced HSPCs derived from either Vav1-cre;Trp53 fl/fl or Vav1-cre;11B3 fl /Trp53 fl mice (Fig. 5a) .
These experiments revealed a clear and substantial p53-independent effect of 11B3 deletion on leukaemia development. Indeed, despite the reduced recombination frequency of the 11B3 allele (Extended Data  Fig. 9a) HSPCs, and succumbed to an aggressive form of AML (Fig. 5b, c and Extended Data Fig. 9b-d ; median overall survival 62 versus 81 days, P = 0.002). RNA-sequencing (RNA-seq) analysis confirmed that 11B3 genes were underexpressed in 11B3-deleted AML cells compared with those in the Trp53-null setting (Fig. 5d) , and gene set enrichment analysis revealed that transcriptional profiles of human 17p13 genes are downregulated in human AMLs harbouring 17p13 deletions (Fig. 5e) . Moreover, 11B3-deleted AMLs were capable of serial transplantation into secondary recipients, where they promoted disease more rapidly than their Trp53-null counterparts (Fig. 5f) . Finally, while the Trp53 
/Trp53
− AML showed reduced sensitivity (Extended Data Fig. 9e, f) . Hence, 11B3 deletions contribute p53-independent phenotypes to AML.
Discussion
This study provides compelling evidence that 17p deletion confers phenotypes beyond those achieved through TP53 loss alone. When considered in light of the established gain-of-function properties of certain missense Trp53 mutations, our results imply that the most frequent somatic event in cancer contributes multiple activities that act independently of Trp53 inactivation to drive tumorigenesis. It therefore seems likely that tumours harbouring TP53 lesionstypically considered a uniform entity-produce distinct phenotypes owing to the nature of the TP53 mutation and the extent of 17p deletion. As such, the models described here will be useful for dissecting precisely how different 17p configurations affect disease onset and ultimately impact therapy response. More broadly, our study 
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METHODS
Genomic analyses of human cancers.
The data on TP53 mutations (including allele frequency) and CNVs in pan-tumours and AML are derived from The Cancer Genome Atlas (TCGA) data in the cBioPortal for Cancer Genomics (http:// www.cbioportal.org/; accessed on 29 October 2014). Only sequenced samples with allele frequency information provided were included in our analysis. Considering potential normal tissue contamination, samples with TP53 mutation allele frequency above 0.6 were considered as a homozygous mutation. The SNP data were visualized in IGV and statistics for AML outcome were analysed in Prism 6. Since cBioPortal only has a few non-Hodgkin lymphoma cases available, we used published data to extract TP53 mutation and deletion information 18, [30] [31] [32] [33] [34] . Clinical outcomes were annotated from follow-up data available within the Gene Expression Omnibus GSE34171 series.
CNV analysis was performed using published AML and DLBCL tumour copy number data in Affymetrix SNP Array 6.0 .cel format (http://cancergenome.nih. gov/) 18, [35] [36] [37] according to GISTIC2.0 (ref. 14). Specifically, the following GISTIC parameters and values were used following the latest TCGA Copy Number Portal analysis version (3 November 2014 stddata__2014_10_17; http://www.broadinstitute. org/tcga/gistic/browseGisticByTissue): core GISTIC version 2.0.22; reference genome build hg19; amplification threshold 0.1; deletion threshold 0.1; high-level amplification threshold 1.0; high-level deletion threshold 1.0; broad length cut-off 0.50; peak confidence level 0.95; cap 1.5; gene-GISTIC, true; arm-level peel-off, true; significance threshold 0.25; join segment size 8; X chromosome removed, false; maximum segments per sample 2,000; minimum samples per disease 40. Conditional 11B3-knockout model. To create a conditional 11B3 chromosome deletion, the MICER strategy was used 15 . Briefly, MICER clones MHPN91j22 (centromeric to Sco1) and MHPP248j19 (telomeric to Alox12) (Sanger Institute) were introduced into AB2.2 ES cells (129S5 strain, Sanger Institute) by sequential electroporation, followed by G418 (neomycin; 180 μg ml ) and puromycin (1 μg ml −1 ) selection, respectively. Successful recombination events were confirmed by Southern blotting using the hybridized probes designated in Supplementary Table 2 as described 38 . The cis-and trans-localizations of two loxP sites in doubly targeted ES cells were further distinguished by PCR with df-F and df-R, or dp-F and dp-R (Supplementary Table 2 ), respectively, after Adeno-cre infection and HAT (Gibco) selection. Correct cis-ES clones in which two loxP sites were integrated into the same allele were used to generate chimaera mice by blastocyst injection. The F1 pups were genotyped with 11B3-F and 11B3-R primers (Supplementary  Table 2 . Eμ-Myc mice with different Trp53 alterations were monitored weekly with disease state being defined by palpable enlarged solid lymph nodes and/or paralysis. Tumour monitoring was done as blinded experiments. For lymphoma generated by transplantation, 1 million Eμ-Myc HPSCs from embryonic day (E)13.5 fetal liver or autoMACS-purified B220 + B progenitor cells isolated from 6-8-week mouse bone marrow were transduced with retroviruses, followed by tail-vein injection into sublethally irradiated (6 Gy, Cs137) C57BL/6 mice (Taconic; 6-8-week old, female, 5-10 mice per cohort) 11, 46 . All recipient mice were randomly divided into subgroups before transplantation and monitored as described earlier. The generation of AML proceeded as previously reported 29 . Briefly, retrovirally infected c-Kit + haematopoietic stem and progenitor cells were transplanted into sublethally irradiated (6 Gy, Cs137) C57BL/6 mice, followed by routine monitoring of peripheral blood cell counts and Giemsa-Wright blood smear staining. For secondary transplantation experiments, 1 million leukaemia cells were transplanted into sublethally irradiated (4.5 Gy) mice. The immunophenotypes of resulting lymphomas and leukaemias were determined by flow cytometry as previously reported using antibodies purchased from eBioscience 11, 29 . Statistical analysis of all survival data was carried out using the log-rank test from Prism 6. No statistical methods were used to predetermine sample size. Retroviral constructs. MSCV-Myc-IRES-GFP and MLS-based retroviral constructs harbouring a GFP or mCherry fluorescent reporter and targeting Ren, Trp53, Eif5a, Nf1 or Mll3 have all been reported before 11, 29, 47 . For the tandem shRNA experiments performed in Fig. 3 , mirE-based shRNAs targeting two different genes were cloned into an MLS-based vector in an analogous fashion to what has been previously described 48, 49 . Retrovirus packaging and infection of HSPCs was done as previously reported 11, 29 .
Apoptosis assay. B220
+ cells were isolated from the bone marrow of 6-week-old Eμ-Myc mice by autoMACS positive selection with anti-B220 microbeads (Militeny Biotech). After overnight culture, cells were infected with retroviruses carrying the indicated shRNAs. Two days after infection, 0.5 × 10 6 cells were washed with PBS followed by annexin V buffer (10 mM HEPES, 140 mM NaCl, 25 mM CaCl 2 , pH 7.4), and incubated at room temperature with Pacific Blue annexin V (BD Biosciences) and propridium iodide (PI; 1 μg ml
; Sigma-Aldrich) for 15 min and analysed on a LSR II flow cytometer (BD Biosciences). For arachidonic acid treatment, pre-B cells were cultured out from bone marrow cells in pre-B cell medium (RPMI1640, 10% FBS, 1% penicillin/streptomycin, 50 μM β-mercaptoethanol, 3 ng ml −1 IL-7). After 3 days culture, pre-B cells were treated with a series concentration of arachidonic acid (Cayman Chemical) for 20 h, followed by annexin V staining as described earlier.
Immunoblotting. Lymphoma cells isolated from lymph nodes of diseased animals were treated with vehicle (PBS) or 1 μg ml −1 adriamycin for 4 h. Whole cell lysates were extracted in cell lysis buffer (Cell Signaling Technology) supplemented with protease inhibitors (Roche), followed by SDS-PAGE gel electrophoresis and blotting onto PVDF membranes (Millipore). Eμ-Myc;Arf −/− lymphoma cell lines were used as a positive control for p53 induction. The p53 antibody used was obtained from Novocastra (NCL-p53-505) and horseradish peroxidase (HRP)-conjugated β-actin antibody from Sigma (AC-15). Alox15b expressions were examined in NIH3T3 cells, which were infected by shRNAs targeting Ren or Alox15b and then selected by G418. Anti-Alox15b antibody is from Sigma (SAB2100110), and HRP-conjugated GAPDH antibody is from ThermoFisher Scientific (MA5-15738-HRP). . An average of 45 million paired reads were generated per sample. At the most the ribosomal reads represented 0.1% and the percentage of mRNA bases was close to 65% on average. The output from the sequencers (FASTQ files) was mapped to the mouse genome (mm9) using the rnaStar (https://code.google.com/p/rna-star/) aligner, with the two-pass mapping methods. After mapping, the expression counts of each individual gene were computed using HTSeq (http://www-huber.embl.de/users/anders/HTSeq), followed by normalization and differential expression analysis among samples using the R/Bioconductor package DESeq (http://www-huber.embl.de/users/anders/ DESeq). Gene set enrichment analysis (GSEA) was performed with Broad's GSEA algorithm. Quantitative PCR. A list of all primers used for PCR analysis is given in Supplementary Table 2. For detection and quantification of 11B3 recombination/ deletion two methods were employed. In both cases genomic DNA (gDNA) was extracted from lymphoma or leukaemia cells using Puregene DNA purification kit (Qiagen). Initially, semi-quantitative PCR was used to detect the recombined 11B3 allele using primers df-F and df-R, generating a 2.2 kb product (Fig. 2d) . The estimated frequency of recombination was determined by dropping gDNA from 11B3 +/− into 11B3 fl/+ at various ratios. For qPCR of the 11B3 deletion (Fig. 2e) , SYBR Green PCR Master Mix (Applied Biosystems) was used and cycling and analysis was carried out on a ViiA 7 (Applied Biosystems). Primers 11B3-Q-F and 11B3-Q-R were used to detect the floxed allele, and to estimate the frequency of 11B3 deletion. Allelic frequency in UPD analysis (Extended Data Fig. 5a ) was determined similarly, in this case with serial dilution of wild-type gDNA into DNase-free water to construct a standard curve. Two-tailed t-test is used for statistics analysis by Prism 6. For p21 gene expression examination by RT-qPCR, RNA was isolated with Trizol, cDNA was synthesized with SuperScript III FirstStrand Synthesis System (Life Technologies) and qPCR was performed as described earlier with primers p21-Q-F and p21-Q-R. Trp53 genomic DNA sequencing. Trp53 exons (2-10) were amplified from genomic DNAs of 11B3-deleted lymphomas by PCR (see Supplementary Table 2 for primer sequences) and subjected to Sanger sequencing. Mutations were called only if detected in sequencing reads carried out in the forward and reverse direction. SNP analysis. SNP analysis of isolated lymphoma (tumour) or tail (normal) genomic DNAs from the same tumour-bearing mouse were carried out by Charles River laboratory. Briefly, a SNP Taqman assay with competing FAM-or VIClabelled probes was used to detect the relevant C57BL/6 and 129S SNPs (D11Mit4 and D11NDS16) as described previously 50 . Copy number profiling. Genomic DNA was extracted from freshly isolated lymphoma cells from one Eμ-Myc;11B3 
